Gil Gilad
Overview
Explore the profile of Gil Gilad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhatla T, Hogan L, Teachey D, Bautista F, Moppett J, Velasco Puyo P, et al.
Blood
. 2024 Aug;
144(21):2237-2247.
PMID: 39158071
Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) have poor outcomes compared with newly diagnosed, treatment-naïve patients. The phase 2, open-label DELPHINUS study evaluated daratumumab (16 mg/kg...
2.
Huibers M, Abla O, Andres M, Balague O, Beishuizen A, Carraro E, et al.
Blood Adv
. 2024 Jan;
8(6):1509-1514.
PMID: 38290136
No abstract available.
3.
Anafy A, Gilad G, Michaan N, Elhasid R, Rosenfeld-Kaidar H, Arad-Cohen N, et al.
Pediatr Blood Cancer
. 2023 Apr;
70(6):e30321.
PMID: 37036274
Background: Intensive chemotherapy for acute lymphoblastic leukemia (ALL) may affect the immune system and potentially the immune memory causing antibodies provided by vaccination to disappear. There are disagreements regarding the...
4.
Elitzur S, Vora A, Burkhardt B, Inaba H, Attarbaschi A, Baruchel A, et al.
Blood
. 2022 Nov;
141(7):743-755.
PMID: 36332176
The development of a second malignancy after the diagnosis of childhood acute lymphoblastic leukemia (ALL) is a rare event. Certain second malignancies have been linked with specific elements of leukemia...
5.
Benish M, Elitzur S, Arad-Cohen N, Barg A, Ben-Harosh M, Bielorai B, et al.
J Fungi (Basel)
. 2022 Apr;
8(4).
PMID: 35448618
Invasive Fusarium species infections in immunocompromised patients occur predominantly in those with hematological malignancies. Survival rates of 20−40% were reported in adults, but data in children are limited. Our retrospective,...
6.
Oz-Alcalay L, Elitzur S, Amitai N, Toledano H, Barzilai-Birenboim S, Avrahami G, et al.
Int J Clin Oncol
. 2021 Dec;
27(2):455.
PMID: 34862941
No abstract available.
7.
Barzilai-Birenboim S, Elitzur S, Nirel R, Ehrenberg M, Zahavi A, Avrahami G, et al.
Br J Haematol
. 2021 Dec;
196(5):1248-1256.
PMID: 34862597
Most childhood acute lymphoblastic leukaemia (ALL) protocols include high-dose steroid therapy. However, the known potential of high-dose steroids to significantly elevate intraocular pressure (IOP) and lead to glaucomatous optic neuropathy...
8.
Oz-Alcalay L, Elitzur S, Amitai N, Toledano H, Barzilai-Birenboim S, Avrahami G, et al.
Int J Clin Oncol
. 2021 Nov;
27(2):448-454.
PMID: 34743265
Background: COVID-19, the novel coronavirus, has caused a global pandemic affecting millions of people around the world. Risk factors for critical disease in adults are advanced age and underlying medical...
9.
Dvori M, Elitzur S, Barg A, Barzilai-Birenboim S, Gilad G, Amar S, et al.
Int J Clin Oncol
. 2021 Jun;
26(8):1569-1574.
PMID: 34145514
Background: COVID-19, the novel coronavirus has caused a global pandemic affecting millions of people around the world. Although children, including children with cancer, have been found to be affected less...
10.
Barzilai-Birenboim S, Yacobovich J, Zalcberg Y, Arad-Cohen N, Avrahami G, Gilad G, et al.
Pediatr Blood Cancer
. 2021 Mar;
68(8):e29033.
PMID: 33788395
Background: Osteonecrosis is a major cause of acute and long-lasting complications of acute lymphoblastic leukemia (ALL) therapy in children. Our study aimed to evaluate the prevalence, characteristics, risk factors, and...